The monoclonal antibody Rmut8 is derived from rituximab comprising H57DE/H102YK/L93NR mutations. Rmut8 shows strongly enhanced ADCC activity than Rituximab. The tumor killing effect of Rmut8 is significantly higher than Rituximab.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-913-sdAb | Recombinant Anti-human MS4A1 VHH Single Domain Antibody | IP, FC, ChiP, Neut | Llama VHH |
HPAB-M0704-YC | Camelid Anti-MS4A1 Recombinant Antibody (HPAB-M0704-YC) | ELISA, FuncS | Camelid VHH |
HPAB-M0705-YC | Camelid Anti-MS4A1 Recombinant Antibody (HPAB-M0705-YC) | ELISA | Camelid VHH |
HPAB-M0706-YC | Camelid Anti-MS4A1 Recombinant Antibody (HPAB-M0706-YC) | ELISA | Camelid VHH |
HPAB-M0707-YC | Camelid Anti-MS4A1 Recombinant Antibody (HPAB-M0707-YC) | ELISA | Camelid VHH |
There are currently no Customer reviews or questions for HPAB-0683-CN. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.